Teva agrees to pay $425M to settle Copaxone kickback case: DOJ
by
Contributor since / Followers
Contributor since / Followers
7 months ago
JHVEPhoto
- Teva (NYSE:TEVA) has agreed to pay $425M to resolve allegations that it paid kickbacks related to its multiple sclerosis drug Copaxone through two co-pay assistance foundations.
- In its complaint, the U.S. government had accused TEVA of violating the Anti-Kickback Statute and causing the submission of false Medicare claims by manipulating the co-pay foundation assistance system, according to a statement by the U.S. Attorney’s Office in Massachusetts.
- More specifically, the government alleged that from 2006 to 2017, Teva conspired with third parties that included a specialty pharmacy and two co-pay assistance foundations to direct its “supposed charitable payments” to patients taking Copaxone, while simultaneously raising the price of the drug, the statement said.
- The U.S. Attorney’s Office said the settlement was reached “after the government’s review of Teva’s financial disclosures concerning its financial condition.”